has appointed Mary M. Fisher as chief executive officer. Ms. Fisher was previously chief operating officer at Acorda Therapeutics, a biotechnology company focused on developing products for the treatment of central nervous system disorders. During her seven years at Acorda, she also served as executive vice president of commercial operations and vice president of marketing and strategic planning. As chief operating officer, she played a key role in Acorda’s success, including its successful IPO and the subsequent strong operating performance and impressive growth in shareholder value. Prior to Acorda, Ms. Fisher was vice president of commercial operations with Cephalon. Her earlier career includes positions with Immunex and Boehringer Ingelheim.